<DOC>
	<DOC>NCT02531035</DOC>
	<brief_summary>This Phase 3 study is designed to demonstrate the net benefit of sotagliflozin versus placebo in patients with T1D.</brief_summary>
	<brief_title>A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Patient has given written informed consent to participate in the study in accordance with local regulations Adult patients 18 years and older with a diagnosis of T1DM made at least 1 year prior to informed consent Patients are being treated with insulin or insulin analog Willing and able to perform selfmonitoring of blood glucose (SMBG) and complete the study diary as required per protocol At the Screening Visit, A1C must be between 7.0% to 11.0% Females of childbearing potential must use an adequate method of contraception and have a negative pregnancy test Use of antidiabetic agent other than insulin or insulin analog at the time of screening Use of sodiumglucose cotransporter (SGLT) inhibitors within 8 weeks prior to screening Chronic systemic corticosteroid use Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>